Vaccibody.com

January 27, 2015 Vacant position- Researcher/Engineer Vaccines/Immunotherapy

Posted at 12:45h in Uncategorized

Vaccibody is a vaccine company dedicated to the development of novel vaccines that overcome shortcomings of current vaccine technologies. The Company’s proprietary vaccine platform increases the antibody and T-cell responses leading to remarkably effective vaccines. Vaccibody plans to initiate its first clinical trial with a...

January 26, 2015 Vaccibody Granted Platform Patent in the US

Posted at 10:33h in Uncategorized

Vaccibody AS is pleased to announce that the U.S. Patent Office has Issued patent No. US 8,932,603 B2 covering the Vaccibody format which can be described as homodimeric modular constructs targeting vaccines to antigen presenting cells designed to increase the immune system’s antibody and T-cell...

December 3, 2014 Vaccibody Granted Platform Patent

Posted at 21:30h in Uncategorized

Vaccibody AS today announces that the European Patent Office (EPO) has granted European patent No. 1599504 covering the Vaccibody format which can be described as homodimeric modular constructs targeting vaccines to antigen presenting cells designed to increase the immune system’s antibody and T-cell responses. This patent...

October 31, 2014 Management change in Vaccibody AS

Posted at 16:58h in Uncategorized

As Vaccibody is entering into a new development phase, the Board of Directors has initiated a search process for a new CEO with experience from clinical development and strategic partnering. On this background, Ole Henrik Brekke, CEO since 2006, has decided to leave the...

July 1, 2014 Vaccibody successfully completes a 35 million NOK financing

Posted at 14:05h in Uncategorized

Vaccibody has in a new share issue completed a 35 MNOK (4.3 million €) financing from existing and new investors. The share issue was significantly oversubscribed. The largest new investor is represented by Datum and partners, which will take a seat in the Board of...

June 2, 2014 Vaccibody AS and Phibro Animal Health Corporation enter into Development and License Agreement.

Posted at 22:00h in Uncategorized

Oslo-, Teaneck, New Jersey, June 2, 2014 The Norwegian vaccine company Vaccibody and Phibro Animal Health Corporation (Nasdaq:PAHC), a global animal health and mineral nutrition company, have signed a global exclusive license agreement which grants Phibro and its affiliates the right to develop, market and sell...

May 20, 2014 Vaccibody in the press

Posted at 08:39h in Uncategorized

A report addressing solutions for strengthening the Norwegian biotechindustry was handed over to the Norwegian government May 20th. Vaccibody was the company being exemplified in the accompanying article in Dagens Næringsliv. Read the article here (Norwegian only)....

April 24, 2014 The Norwegian Cancer Society invests 500 000 € in Vaccibody

Posted at 13:53h in Uncategorized

The Norwegian Cancer Society (NCS) has recently organized a investment fund for Norwegian companies with a focus on developing novel cancer therapies. With the promising development of VB10.16, Vaccibody’s therapeutic vaccine against HPV induced precancerous lesions, NCS has decided to place their first investment in...

March 7, 2014 Innovation Award for Vaccibody concept

Posted at 13:54h in Uncategorized

New targeting vaccines for aquaculture based on the Vaccibody concept won 1st prize in Marine Innovation Day (MID) Innovation Award in a conference held in Bergen early in March. The vaccineproject run by researchers at the Norwegian Veterinary Institute and University of Oslo aims to utilize...

September 13, 2013 New Vaccibody publication

Posted at 13:55h in Uncategorized

The newly published paper by Gunnveig Grodeland et al: DNA Vaccine that Targets Hemagglutinin to MHC Class II Molecules Rapidly Induces Antibody-Mediated Protection against Influenza, describes the vaccibody platform as a robust and effective vaccine for prophylactic use. The paper can be downloaded here...